Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.39 |
| ▸ | FABP4 | P15090 | 1/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 4/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.33 |
| ▸ | LIPC | P11150 | 2/20 | 0.33 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9963519 | 0.88 | PTGS2 (0.49) | PTGS2FABP4ALDH1A1ACKR3 | |
| SCHEMBL9963597 | 0.84 | PTGS2 (0.38) | PTGS2FABP4ACKR3 | |
| SCHEMBL9963566 | 0.83 | PTGS2 (0.47) | PTGS2FABP4LIPGLIPCALDH1A1 | |
| SCHEMBL9963564 | 0.82 | PTGS2 (0.43) | PTGS2FABP4ALDH1A1 | |
| SCHEMBL9963575 | 0.79 | TP53 (0.41) | PTGS2LIPGALDH1A1ACHE | |
| SCHEMBL9963556 | 0.79 | PTGS2 (0.48) | PTGS2FABP4ALDH1A1 | |
| SCHEMBL9963579 | 0.77 | PTGS2 (0.38) | PTGS2FABP4LIPGALDH1A1 | |
| SCHEMBL9963549 | 0.76 | ACHE (0.46) | PTGS2ALDH1A1ACHE | |
| SCHEMBL9963583 | 0.74 | PTGS2 (0.42) | PTGS2FABP4ALDH1A1 | |
| SCHEMBL9963551 | 0.74 | PTGS2 (0.39) | PTGS2FABP4ACHEACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2032583-B1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2014-11-19 | — | — | EP | disclosed |
| US-8203001-B2 | Chemical compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-19 | — | — | US | disclosed |
| US-8203001-B2 | Chemical compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-19 | — | — | US | disclosed |
| US-20090258857-A1 | CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-15 | — | — | US | disclosed |
| US-20090258857-A1 | CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-15 | — | — | US | disclosed |
| WO-2007144370-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258857-A1 | CHEMICAL COMPOUNDS | CCNA1, CCNT1, MKI67 | PTGS2 2872/4885FABP4 1794/4885SSTR4 2264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.